<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "trastuzumab emtansine (KADCYLA) inj VIAL">
<dose><value>3.6</value>
<value>3</value>
<value>2.4</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drugname><value>trastuzumab emtansine (KADCYLA) inj VIAL</value>
</drugname><strength><value>100 mg</value>
</strength><frequency><value>ONCE</value>
</frequency><instruction><value>DAY 1 of 21 day cycle. Administer dose diluted in 250 mL sodium chloride 0.9%. Administer dose over 90 minutes ans observe patient for 90 minutes post-infusion. If well tolerated, subsequent infusions may be administered over 30 minutes with patient observed for 30 minutes post-infusion.</value>
</instruction><volume><value></value>
</volume><units><value>mg/kg</value>
</units><additionalnotes><value>trastuzumab emtansine (Kadcyla) is not interchangeable with trastuzumab (Herceptin).</value>
</additionalnotes><population><value>ADULT</value>
</population><indicationprn><value></value>
</indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=6741</value>
</backgroundinformation><prninformation><value></value>
</prninformation><ahsformularystatus><value>Formulary with Restrictions.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose><value>YES</value>
</maximumprndose></drug>